13 assets in Iatrogenic Disease

Therapeutic assets addressing Iatrogenic Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nepenthe Iatrogenic Disease	Tiva Group	P4	BB (65)
Paliperidone Iatrogenic Disease	Consorcio Centro de Investigación Biomédica en Red (CIBER)	P4	BB (65)
Duloxetine Iatrogenic Disease	European Organisation for Research and Treatment of Cancer - EORTC	P3	B (60)
Furosemide Iatrogenic Disease	European Organisation for Research and Treatment of Cancer - EORTC	P3	B (60)
Modified Si Jun Zi Tang Iatrogenic Disease	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Rituximab Iatrogenic Disease	Columbia University	P2	CCC (53)
Tocilizumab Iatrogenic Disease	Columbia University	P2	CCC (53)
gc203 til Iatrogenic Disease	Shanghai Juncell Therapeutics	Early P1	C (39)
TIL Iatrogenic Disease	Shanghai Juncell Therapeutics	Early P1	C (39)
Propofol Iatrogenic Disease	Cairo University	N/A	D (30)